Related Experiment Video
Updated: Jun 22, 2026
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
Id1/Id3 knockdown inhibits metastatic potential of pancreatic cancer
Yasutaka Shuno1, Nelson H Tsuno, Yurai Okaji
1Department of Surgical Oncology, University of Tokyo, Tokyo, Japan. shuu@tkg.att.ne.jp
Background:
The Id (inhibitor of DNA binding/differentiation) proteins belong to the helix-loop-helix transcriptional regulatory factors, and play important roles in tumor development. Previously, we and others have shown that targeting Id in tumor cells could have important clinical implications. In the present study, we aimed to evaluate the effects of Id inhibition in human pancreatic cancer cells.
Materials And Methods:
Id1 and Id3 were stably double-knockdown in human pancreatic cancer cell line MIA-Paca2 by means of RNA interference. Expression of Id and integrins were analyzed by flow-cytometry. Cell proliferation was evaluated by MTS assay. Migration was measured by wound closure assay. Adhesion assay was performed to evaluate binding capacity for different extracellular matrix proteins. Finally, in vivo properties of tumor cells were observed in a mouse model of peritoneal metastasis.
Results:
Id1/Id3 double-knockdown resulted in decreased ability of pancreatic cancer cells to proliferate and migrate. In addition, Id1/Id3 double-knockdown caused decreased expression of integrins alpha3, alpha6, and beta1, and consequently reduced adhesion of tumor cells to laminin. Finally, peritoneal metastases of Id1/Id3 double-knockdown tumor cells were significantly reduced.
Conclusions:
We concluded that the Id proteins play a pivotal role in the development of peritoneal metastasis of pancreatic cancer, and consequently, their targeting would be a novel strategy for the prevention and treatment of pancreatic cancer.
Insights
Inhibiting Id proteins (inhibitor of DNA binding/differentiation) significantly reduced pancreatic cancer cell proliferation, migration, and peritoneal metastasis. Targeting Id proteins offers a novel therapeutic strategy for pancreatic cancer treatment.
Area of Science:
- Molecular Biology
- Oncology
- Cancer Research
Background:
- Id proteins are helix-loop-helix transcriptional regulators implicated in tumor development.
- Previous research indicates targeting Id proteins in tumor cells has clinical relevance.
- This study investigates the impact of Id inhibition in human pancreatic cancer.
Purpose of the Study:
- To evaluate the effects of inhibiting Id1 and Id3 proteins in human pancreatic cancer cells.
- To assess the role of Id proteins in pancreatic cancer cell proliferation, migration, adhesion, and metastasis.
Main Methods:
- Stable double-knockdown of Id1 and Id3 in MIA-Paca2 pancreatic cancer cells using RNA interference.
- Analysis of Id and integrin expression via flow cytometry.
- Assessment of cell proliferation (MTS assay), migration (wound closure assay), and adhesion (ECM binding assay).
- In vivo evaluation in a mouse model of peritoneal metastasis.
Main Results:
- Id1/Id3 double-knockdown significantly decreased pancreatic cancer cell proliferation and migration.
- Reduced expression of integrins alpha3, alpha6, and beta1 was observed, leading to decreased tumor cell adhesion to laminin.
- Peritoneal metastases were significantly reduced in tumor cells with Id1/Id3 double-knockdown.
Conclusions:
- Id proteins play a critical role in the development of pancreatic cancer peritoneal metastasis.
- Targeting Id proteins represents a novel therapeutic strategy for preventing and treating pancreatic cancer.
- Inhibition of Id proteins may offer a new avenue for clinical intervention in pancreatic cancer.
